Reaction
Administration Site Pain reporting signals
As of the last recalculation, Administration Site Pain appears in 1,120 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is EPINEPHRINE (PRR 26.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Epinephrine | 86 | 26.4 | 26.4 |
| Adrenalinum | 41 | 19.0 | 19.0 |
| Lidocaine | 53 | 17.7 | 17.7 |
| Lidocaine, Menthol | 44 | 17.1 | 17.1 |
| Lidicaine | 43 | 16.9 | 17.0 |
| Burn Relief | 43 | 16.9 | 17.0 |
| Lidocaine Hydrochloride And Epinephrine | 43 | 16.9 | 16.9 |
| Diphenhydramine | 51 | 15.7 | 15.7 |
| Lidocaine 4% | 44 | 15.6 | 15.6 |
| Lidocaine Hydrochloride And Epinephrine Bitartrate | 43 | 15.5 | 15.5 |
| Golimumab | 59 | 13.4 | 13.4 |
| Tranexamic Acid | 6 | 12.6 | 12.6 |
| Iron Sucrose | 6 | 11.8 | 11.8 |
| Treprostinil | 69 | 10.8 | 10.8 |
| Miconazole Nitrate | 5 | 10.7 | 10.7 |
| Testosterone Cypionate | 4 | 8.3 | 8.4 |
| Teduglutide | 6 | 8.3 | 8.3 |
| Alirocumab | 11 | 8.2 | 8.2 |
| Crisaborole | 4 | 7.8 | 7.8 |
| Bimekizumab | 8 | 7.0 | 7.0 |
| Daptomycin | 3 | 6.1 | 6.1 |
| Benralizumab | 6 | 5.6 | 5.6 |
| Asfotase Alfa | 3 | 5.6 | 5.6 |
| Ambrisentan | 36 | 5.5 | 5.5 |
| Fremanezumab-Vfrm | 3 | 4.9 | 4.9 |
| Rimegepant Sulfate | 3 | 4.4 | 4.4 |
| Romosozumab-Aqqg | 3 | 4.1 | 4.1 |